PTC Therapeutics Inc. (PTCT) was one of the Russell 2000's biggest losers for Monday January 04 as the stock slid 6.17% to $30.40, a loss of $-2 per share. Starting at an opening price of $31.60 a share, the stock traded between $30.09 and $31.89 over the course of the trading day. Volume was 530,749 shares over 4,814 trades, against an average daily volume of 976,297 shares and a total float of 34.27 million.
The losses send PTC Therapeutics Inc. down to a market cap of $1.04 billion. In the last year, PTC Therapeutics Inc. has traded between $78.72 and $22.67, and its 50-day SMA is currently $29.13 and 200-day SMA is $44.41.
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.
PTC Therapeutics Inc. is based out of South Plainfield, NJ and has some 193 employees. Its CEO is Stuart W. Peltz.
For a complete fundamental analysis analysis of PTC Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for PTCT. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.